OBJECTIVE: Positron emission tomography (PET) was used to compare cerebral metabolic patterns in @entity161 subjects with predominantly negative symptoms ( @entity2026 , affective flattening, avolition, and @entity73 ) and in those with predominantly positive symptoms. METHOD: Fourteen right-handed male subjects with DSM-IV @entity161 were assigned to groups with predominantly negative or predominantly positive symptoms on the basis of their post-drug-washout scores on the Positive and Negative Syndrome Scale. The @entity1 were compared to seven age- and gender-matched normal volunteers. PET scans with @entity419 were obtained during a degraded Continuous Performance Task to measure absolute @entity413 metabolic rates. Statistical parametric mapping was used to estimate the regional metabolic differences between groups. RESULTS: The subjects with predominantly negative symptoms had significant differences in @entity413 metabolic rates, compared to both the subjects with predominantly positive symptoms and the normal subjects. Negative symptom subjects had a lower @entity413 metabolic rate in the right hemisphere, especially in the temporal and ventral prefrontal cortices, compared to the other groups, and higher metabolic rates in the cerebellar cortex and in the lower deep cerebellar nuclei. Negative symptom subscale scores were negatively correlated with @entity413 metabolic rates for most of the brain areas that differentiated subjects with predominantly negative symptoms from those with predominantly positive symptoms. CONCLUSIONS: @entity161 subjects with predominantly negative symptoms have greater metabolic abnormalities than subjects with predominantly positive symptoms, particularly in frontal, temporal, and cerebellar circuitry. These results are consistent with abnormalities in corticocortical, corticobasal ganglia, mesocortical @entity935 , and cerebellar-thalamic-prefrontal circuits, which may underlie the negative symptoms of @entity161 .

A PET study of the pathophysiology of negative symptoms in XXXX . Positron emission tomography.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['[(18)F]fluorodeoxyglucose'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity73 :: ('MESH:D003072', 'Disease') :: ['attentional impairment'] @entity2026 :: ('MESH:D001037', 'Disease') :: ['alogia'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenic', 'schizophrenia', 'Schizophrenic'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']
